The early detection of lung cancer using thoracic CT has been widely demonstrated in multiple international trials to objectively increase cure rates. Now the international focus is on effective and economical implementation. Increasingly, it is emerging that thoracic CT screening is also detecting a range of early tobacco-related diseases including cardiovascular disease and chronic obstructive pulmonary disease. These three diseases comprise the ‘BIG3’, as they collectively account for close to half of the premature deaths globally. Thoracic CT screening presents a unique opportunity to integrate care for this high risk cohort with a single imaging examination. We plan to develop optimized protocols for evaluation of these major diseases, explore challenges and define solutions in enabling implementation, especially for economically disadvantaged countries across the world. A core strategy in achieving this ambitious goal is to leverage the use of AI processes across the continuum of care, including its use for risk assessment, disease detection and managing disease interventions.
Planning Committee
Claudia Henschke
PhD, MD
Icahn School of Medicine at Mount Sinai New York, NY
Matthijs Oudkerk
MD, PhD
University of Groningen Groningen, Netherlands
David Yankelevitz
MD
Icahn School of Medicine at Mount Sinai
New York, NY
James Mulshine
MD
Rush University
Chicago, IL
John Field
MA, PhD, BDS, FRCPath
University of Liverpool
Liverpool, United Kingdom
Mario Silva
MD, PhD
University of Parma
Parma, Italy
Witold Rzyman
MD, PhD
Medical University of Gdańsk
Gdańsk, Poland
Program
Thursday, March 19, 2026
| 08:30–09:00 | Introduction to Sessions Welcome Address: W Rzyman, M Markuszewski, J Kraszewski |
| 09:00–09:30 | Research Updates Meeting Format: C Henschke, M Oudkerk, D Yankelevitz |
| 09:30–10:45 |
Session 1: Understanding Disease Burden and Integrated Screening in Eastern Europe: Established Programs and Initiatives
|
| 10:45–11:00 | Coffee Break |
| 11:00–12:00 | Session 1: Panel Discussion (AGILE Mission in Eastern Europe) Moderator: D Yankelevitz Panelists: H Chen, H de Koning, J Field, W Rzyman, E Taioli |
| 12:00–13:00 |
Session 2: Critical Considerations in Moving Towards Integrated BIG3 Screening
|
| 13:00–13:45 | Session 2: Panel Discussion (What are the shared opportunities?) Panelists: I Gipp, B Li, V Liebenberg, S Schmidt, C van der Aalst |
| 13:45–14:45 | Lunch Break |
| 14:45–15:35 |
Session 3: Technology Innovations
|
| 15:35–16:00 | Session 3: Roundtable |
| 16:00–16:45 | Marilyn and Jim Simons Keynote Lecture Introduction: C Henschke Impact of changing image quality on AI performance: R Avila |
| 16:45–17:00 | Coffee Break |
| 17:00–17:45 | Session 4: Diagnostic Case Review Moderators: M Jelitto, D Shaham Panelists: J Gratama, E Kazerooni, A Kerpel-Fronius, K Sienkiewicz, M Silva |
Friday, March 20, 2026
| 08:30–09:45 |
Session 5: Clinical Impact of Early Detection of Cardiovascular Disease Moderators: A Stillman, P Raggi
|
| 09:45–10:30 |
Session 5: Panel Discussion Introduction: P Raggi Panelists: J Gratama, M Jaguszewski, SH Lee, M van Assen, A Walstra |
| 10:30–10:45 | Coffee Break |
| 10:45–11:45 |
Session 6: AI for Early Detection of Big 3 Moderators: D Yankelevitz, M Oudkerk
|
| 11:45–12:30 |
Session 6: Panel Discussion Introduction: Risk vs. Diagnosis: R Yip Panelists: J Vogel Claussen, E Kazerooni, A Stillman, S Zheng |
| 12:30–13:30 | Lunch Break |
| 13:30–14:15 |
Session 7: Biomarker Readiness for Implementation? Moderators: J Field, J Mulshine
|
| 14:15–15:00 |
Session 7: Panel Discussion Moderators: J Field, J Mulshine Panelists: C Amos, H de Koning, I Gipp, V Liebenberg, S Schmidt, S Zheng |
| 15:00–15:15 | Coffee Break |
| 15:15–16:15 |
Session 8: Considerations for actionability: invasive vs. non-invasive procedures Moderators: N Altorki, D Yankelevitz
|
| 16:15–17:00 |
Session 8: Panel Discussion Panelists: R Dziedzic, M Infante, K Lau, W Rzyman, S Senan/R Dziadziuszko, JC Trujillo, R Santos |
Saturday, March 21, 2026
| 09:00–10:00 |
Session 9: New Therapeutics Approaches
|
| 10:00–10:45 | Session 9: Panel Discussion Moderators: W Rzyman, C Aigner Panelists: R Dziadziuszko, M Infante, R Santos, S Senan |
| 10:45–11:45 | Session 10: Therapeutic Case Review Moderators: W Rzyman, D Yankelevitz Panelists: C Aigner, N Altorki, N Leighl, S Senan |
| 11:45–12:15 | Coffee Break |
| 12:15–13:15 |
Session 11: Monitoring Treatment Effectiveness for Stage I Lung Cancers
|
| 13:15–14:15 | Lunch + ePoster Presentations & Awards(for information and submission: agile.eposter@i-dna.org) Chairs: D Shaham, M Silva |
| 14:15–15:00 |
Session 12: Advocacy in Eastern Europe and the Potential to Collaborate
|
| 15:00–15:45 |
Session 13: Special Issues to be Published Presentations of manuscripts-in-progress |
| 15:45–16:00 | Closing Statements and Future Meetings C Henschke, M Oudkerk |
Sponsors
Terms and Conditions
Contact
m.zareba@90consulting.pl
+48 536 770 087
90 Consulting
ul. Bagatela 10/19
Warszawa